Kornimate/medical-research-clean huggingface dataset:
therapeutic use of convalescent plasma in the treatment of patients with moderate to severe covid-19

Conditions: COVID-19; SARS-CoV-2 Infection; Severe Acute Respiratory Syndrome Coronavirus 2

Summary: a prospective, randomized, placebo-controlled, double-blinded, phase iii clinical trial of the therapeutic use of convalescent plasma in the treatment of patients with moderate to severe covid-19

full title: a prospective, randomized, placebo-controlled, double-blinded, phase iii clinical trial of the therapeutic use of convalescent plasma in the treatment of patients with moderate to severe covid-19. short title: protect-patient study aim: assess the safety and efficacy of covid-19 convalescent plasma (ccp) as a therapeutic treatment for hospitalised patients with moderate to severe covid-19 study design: randomised, double-blinded, placebo-controlled, phase iii clinical trial intervention: randomised 1:1 to either ccp plus standard of care (soc) or to soc plus placebo (200 ml normal saline) active agent: a single unit of approximately 200-250 ml of ccp that contains anti-sars-cov-2 collected by plasmapheresis from a volunteer who recovered from covid19 with soc as determined by local practice and guidelines. placebo: a single unit of 200 ml normal saline with soc as determined by local practice and guidelines sample size: 600 study population: consenting adult inpatients with moderate to severe covid-19, not requiring invasive ventilation, who are admitted to a participating public or private sector hospital and who are not enrolled in another covid-19 treatment trial. settings: participating public and private sector hospitals in south africa

Eligibility criteria:
inclusion criteria: * laboratory confirmed sars-cov-2 by positive rt-pcr on any respiratory sample; * age ≥ 18 years; * require hospital admission for covid-19 pneumonia as defined by the presence of pulmonary infiltrates on chest x-ray; * moderate to severe covid-19 disease, defined as: spo2 ≤ 93% on room air; plus requiring non-invasive oxygen therapy (who r\&d bosci 4 or 5 * signed informed consent; * pregnant women will be allowed to participate. exclusion criteria: * current participation in another therapeutic clinical trial for covid-19; * invasive mechanical ventilation; * expected survival \< 24 hours based on clinical assessment (however, the study does not exclude critically ill patients who are not, due to resource limitations, candidates for critical care admission and/or mechanical ventilation); * known hypersensitivity to immunoglobulin or any components of the formulation;
effect of laser acupuncture on postnatal pelvic girdle pain

Conditions: Laser Acupuncture; Pelvic Pain; Post Natal

Summary: this study was done to evaluate the effect of laser acupuncture on pelvic girdle pain postnatal females' patients.

postnatal pelvic girdle pain might be addressed as a gynecologic challenge in the 21 century in women of all ages and it frequently occur simultaneously. various forms of postnatal pelvic girdle pain were aggravated by moderate daily activities. laser acupuncture is a therapeutic modality focuses on selected acupoints in a safe maneuver

Eligibility criteria:
inclusion criteria: * fifty-four women suffering from postnatal pelvic girdle pain, clinically diagnosed by a gynecologist. * their ages were ranged from 20-45 years old. * their body mass index (bmi) was ranged from 25-29.9 kg/m2. * they shouldn't have any musculoskeletal or neurological disorders. exclusion criteria: * current pregnancy. * malignant condition * history of acute infection * neurological problem * mental problem to prevent evaluation and cooperation. * having uncontrolled metabolic diseases like diabetes and thyroid disease. * athletic females.
prevalence of low back and pelvic pain in pregnant women

Conditions: Low Back Pain; Pelvic Pain

Summary: the purpose of this study is to determine the prevalence of low back and pelvic pain in spanish pregnant women. the results should allow for the identification of factors associated with a greater risk of having it during pregnancy. once risk factors are identified, other studies can assess the effectiveness of measures to reduce this pain.

validated methods were used to gather data on the prevalence of lbp, lp and pgp, anthropometric and socio-demographic characteristics, history of lbp, obstetrical history, physical activity before and during pregnancy, mattress and sleep characteristics, disability, anxiety, and depression. separate multiple logistic regression models were developed to identify the variables associated with lbp, lp and pgp.

Eligibility criteria:
inclusion criteria: * a pregnancy of 28 weeks or more * able to understand, read and write spanish * seen at participating health centers or hospitals in the study * signs informed consent form exclusion criteria: * refusal to participate in the study * being under 18 years of age or legally mentally incapacitated * having a diagnosis of illnesses that can cause back pain

Keywords: low back pain pelvic pain pregnancy
prospective cohort follow-up of french patients with profound and multiple disabilities: healthcare pathways and quality of life among patients and their families

Conditions: Paraparesis; Tetraparesis; Hemiparesis; Ataxia; Neuromuscular Disorders; Extrapyramidal Motor Disorders

Summary: the studies conducted so far concerning the medical and paramedical cares provided to patients with profound and multiple disabilities (pmd) often show important limitations: samples are too small or very heterogeneous, generally constituted of children only; studies are mainly cross-sectional and retrospective, focusing on very specific issues instead of assessing health and quality of life from a more global perspective... so far, the investigators found no published data from a prospective cohort study involving a representative sample of patients with pmd. the present project aims to set up such a cohort so as to describe for the first time the natural history of french patients with pmd as well as the cares they receive at home or within the different dedicated structures in france. this cohort will also make it possible to identify the factors responsible for differences in the cares patients are provided, the consequences of these differences on their health and their quality of life (and those of their relatives) as well as the evolutions of these data over time. it will then allow for assessing the effectiveness of the french healthcare system to care for patients with pmd as well as building a frame of reference regarding the best cares to provide to these patients. the primary goal of this study is to identify the determinants of health among patients with pmd.


Eligibility criteria:
inclusion criteria: * age \> 3 years old, * patient with health insurance, * causal brain injury before the age of 3, * intellectual quotient \< 40 or not assessable, * motor disability: paraparesis, tetraparesis, hemiparesis, ataxia, neuromuscular disorders, or extrapyramidal motor disorders, * score at the gross motor function classification system \> 3, * score at the functional independence measure \< 55. exclusion criteria: subject declaring benefit "psychotropic treatment which" significantly alter the reasoning, discernment or judgment.
stereotactic radiosurgery combination with anlotinib for limited brain metastases in nsclc

Conditions: Stereotactic Body Radiation Therapy

Summary: the purpose of this study is to determine whether stereotactic radiosurgery combination with anlotinib could improve the efficacy and outcomes for non-small cell lung cancer with limited brain metastases.

this is a retrospective study. the purpose of this study is to determine whether stereotactic radiosurgery combination with anlotinib could improve the efficacy and outcomes for non-small cell lung cancer with limited brain metastases. patients in anlotinib group took anlotinib 1 week before the mri-based simulation，12mg/d qd，day1\~14, 21d/cycle. patients in sbrt group took no anti-angiogenic drugs. all patients received sbrt for brain metastases.

Eligibility criteria:
inclusion criteria: 1. patients pathologically diagnosed as non-small cell lung cancer, with brain metastases and measurable lesions; 2. patients aged between 18 -80 years; with expected survival time\>3 months. 3. patients with no more than 5 brain metastases 4. patients with normal organ function within 7 days prior to treatment, the following criteria are met: 1. blood routine examination criteria : i) hemoglobin (hb) ≥90g/l; ii) absolute neutrophil count (anc) ≥1.5×10e9/l; iii) platelet (plt) ≥80×10e9/l; b) biochemical tests meet the following criteria: i) total bilirubin (tbil) ≤1.5 times of upper limit of normal (uln); ii) alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤2.5 uln, if liver metastasis occurred, alt and ast ≤5 uln; iii) serum creatinine (cr) ≤1.5 uln or creatinine clearance (ccr) ≥60ml/min; exclusion criteria: 1. patients who had previously used antiangiogenic agents within 1 month; 2. patients with small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer); 3. patient with lung squamous cell carcinoma that involved pulmonary hilar, or non-small cell lung cancer with hemoptysis; 4. patients with cerebral infarction and cerebral hemorrhage; 5. patients without perilesional edema； 6. patients with more than grade 2 (nci-ctcae v4.0) acute toxicity reaction due to any previous treatment. 7. patients with factors that affect oral medication (such as cannot swallow, chronic diarrhea and intestinal obstruction, etc.); 8. patients with visceral dissemination or severe symptoms, which could cause death in short term; 9. patients with any other severe and/or uncontrolled disease; 10. patients who received a surgery, a biopsy or a significant traumatic injury within 1 month; 11. patients with any signs or medical history of bleeding, unhealed wounds, ulcers or fractures, regardless of the severity; 12. patients underwent artery or venous thrombotic events within 2 months, such as deep vein thrombosis and pulmonary embolism; 13. patients with a history of psychotropic medicine abuse and cannot quit or have mental disorders; 14. patients with disease which will severely endanger their security and could not complete this study, according to the judgement of researchers；
watchpat compared to psg at 8500'

Conditions: Sleep Disorder; Breathing-Related

Summary: subjects who consent to participate in the research will undergo a simultaneous recording of inlab psg and watchpat200 for comparing the watchpat data to psg at an altitude of 8500'.

the efficacy of the wp200u will be evaluated by comparing it to the psg manual scoring of sleep disordered breathing (sdb) parameter using the psg manual scoring as a "gold standard"

Eligibility criteria:
inclusion criteria: * male and females ≥ age 17yrs * subject is able to read understand and sign the informed consent form. * willing to sleep with the wp200u and psg simultaneously in the sleep lab. exclusion criteria: * use of one of the following medications: alpha blockers, short acting nitrates (less than 3 hours before the study). * any condition that in the opinion of the investigator may adversely affect the safety of the patient or would limit the patient ability to complete the study.
vaginal estriol before and vaginal surgery for prolapse

Conditions: Genital Prolapse

Summary: the purpose of this study is to determine whether the vaginal estriol before vaginal surgery for pelvic statics disorders is more efficacy of no estriol treatment on vaginal health and quality of life.

the aim of this randomized study was to evaluate the efficacy of low concentration of vaginal estriol gel (0.005%, 50 micrograms/1 g vaginal gel) in women with pelvic statics disorders before vaginal surgical treatment (group a), assessing the vaginal dryness, dysuria, vaginal maturation index (vmi), ph and the vaginal health index (vhi). secondary, to investigate the changes of sexual function and qol. women without pre surgical estriol treatment constituted the control group (group b).

Eligibility criteria:
inclusion criteria: * genital dryness, * irritation/burning/itching of vulvas or vagina * decreased lubrication with sexual activity * discomfort or pain with sexual activity * decreased arousal, orgasm, desire * dysuria. exclusion criteria: * previous surgeries for pelvic organ prolapse * urinary incontinence * usage of medication * chronic medical illness * body mass index (bmi) ≥ 35 kg/m2 * endometrial thickness equal to or greater than 4 mm * abnormal uterine bleeding * hormone-dependent malignancies * history of thromboembolic disease * liver disease * usage of ht for less than 3 months * usage of phytoestrogens within 1 month before the start of the study * partner affected by sexual disorder * conflicting with the partner

Keywords: estriol prolapse quality of life vaginal health vaginal surgery
comparison between subacromial ultrasound guided and systemic steroid injection for frozen shoulder

Conditions: Frozen Shoulder; Shoulder Pain; Bursitis

Summary: this study aim to compare the efficacy of guteal muscle injection and subacromial ultrasound guided injection to treat frozen shoulder. firstly, in order to calculate the sample size correctly, we start the preliminary study. besides, in order to propose clinical new technology which combines the advantages of the two therapies, improve the efficacy ratio of frozen shoulder therapy, and provide a frozen shoulder treatment plan according to health economics.

in recent years, there have been studies suggesting that small doses of corticosteroid systemic medication and joint local injection to treat shoulder sleeve disease is equivalent, frozen shoulder is clinically in addition to shoulder sleeve disease another common cause of shoulder pain disease, local injection of small dose of corticosteroid is a clinically commonly used treatment of frozen shoulder mature therapy, however, because of the risk of joint infection and other serious complications, and it's personnel experience depended and high qualification requirements, resulting in higher treatment costs. however, it has not been widely used in clinical applications and is generally used as a second-line therapy for the treatment of frozen shoulders. there are studies suggesting that joint cavity hormone injection may be mainly effective through its systemic effect, however, there is currently no random blind control study comparing small doses of hormone systemic injection with local injection of shoulder joints to freeze shoulder, if the equivalence of the two can be confirmed through such studies will greatly change the clinical treatment of frozen shoulders, with hip injection and other systemic medication will provide great health economic advantages, and can avoid the inherent risk of joint cavity injection, reduce the social cost of frozen shoulder treatment.

Eligibility criteria:
inclusion criteria: * 1. primary frozen shoulder * 2. older than 18 years of age and less than 75 years of age * 3. the shoulder pain vas score is greater than 3 points and lasts at least 1 month and less than 9 months * 4. the passive activity of the side shoulder joint in at least 2 directions in the three directions of front, internal and outer rotation decreased by more than 30 degrees compared to the side shoulder joint or the normal reference value * 5. corticosteroid injections were not given within 3 months of visit exclusion criteria: * 1. a history of trauma, osteoarthritis, tumors, etc. * 2. combined shoulder sleeve injury with magnetic resonance or b-mode ultrasound confirmed * 3. there is a history of corticosteroid injections within 3 months of visit * 4. suffer from a partial infection of the side shoulder or other cases where there is a contraindication of shoulder injection * 5. both side shoulder joints become ill at the same time * 6. the patient has not signed an informed consent form
early la venting during venoaterial ecmo support

Conditions: Cardiogenic Shock; Extracorporeal Membrane Oxygenation Support; Refractory Pulmonary Edema

Summary: the evolve-ecmo(early left atrial venting versus conventional treatment for left ventricular decompression during venoarterial extracorporeal membrane oxygenation support) study is a randomized controlled trial to evaluate the prognostic effect of early la venting(when detect b-line on serial lung ultrasound) on weaning va-ecmo support in refractory cs who receive va-ecmo support. the aim of evolve-ecmo trial is to test the hypothesis that early la venting would result in a significant reduction in failure of weaning ecmo support in refractory cs.


Eligibility criteria:
inclusion criteria: * subject was \> 18 years of age. * subjects who underwent successful va-ecmo support * subjects with refractory cardiogenic shock who had pulmonary edema confirmed by chest x ray or lung sonogram. * the patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate institutional review board/ethical committee of the respective clinical site. exclusion criteria: * subject was \<80 years of age * pregnant and/or lactate women * subjects who underwent va-ecmo after recent open heart surgery * subjects who underwent va-ecmo after non-cardiogenic arrest(trauma, hypothermia, submersion, drug overdose, asphyxia, intracranial hemorrhage etc) * severe bleeding tendency * terminal malignancy * known severe irreversible brain damage * subject was unable to provide written informed consent or participate.

Keywords: cardiogenic shock extracorporeal membrane oxygenation support left atrial venting
a comparison of the efficacy of interdental floss to water flosser around dental implants

Conditions: Implant Site Bleeding

Summary: the primary objective of this study was to compare two different interproximal devices, water flosser and dental floss around implants in several clinical parameters

this study was a randomized, controlled clinical trial in a single center. all clinical measurements were taken by a single blinded investigator (periodontal resident) while a single dental hygienist was responsible for prophylaxis and delivery of oral hygiene instructions to the study participants. at each appointment 5 clinical parameters were recorded: full mouth plaque score (fmps) and quigley-hein plaque index (qhi) of the implants after the use of a disclosing solution, probing depth (pd), bleeding on probing (bop) of the study implants recorded at 6 sites (distobuccal, mid-buccal, mesiobuccal, distolingual, mid-lingual and mesiolingual) using a unc 12 colorvue probe and the width of the keratinized tissue (kt) at the buccal surface of the study implants. randomization between the 2 groups was achieved using computerized randomization scheme (https://en.calc-site.com/randoms/grouping). group a (control): patients were instructed to floss with tepe bridge and implant floss once a day, preferably at nighttime. group b (test): patients were provided with waterpik water flosser and instructed to water floss around the implant once a day, preferably at nighttime. during each appointment the study investigator measured clinical parameters and participants received oral hygiene instructions (ohi) and supportive periodontal therapy (spt) by a single dental hygienist. once the study was concluded patients were asked to fill-out a 2 question questionnaire inquiring how much they liked their interproximal device and how easy it was to be used in a scale 1 to 5.

Eligibility criteria:
inclusion criteria: * patients that present with at least a single implant with a screw-retained crown * patients with general good health that do not have a condition contra-indicating routine dental treatment * patients that are compliant with the research protocol and methods * patients that have read, understood and signed the informed consent form exclusion criteria: * patients with implants with cemented crowns * patients with any contact hypersensitivity to the related materials used in the study * tobacco users (vaping included) * patients unwilling to sign the informed consent form or follow the protocol of the study

Keywords: dental implants water flosser
exploration of the relationship between sexual health and pain in the context of cancer in france

Conditions: Pain; Cancer; Survivorship

Summary: the goal of this observational study is to explore the relationship between pain and sexual health in the context of cancer (cancer patients and cancer survivors). the main question it aims to answer is: - does pain interfere with sexual health in cancer patients and cancer survivors?

participants will be recruited through french cancer patient associations and will be invited to complete an online survey questionnaire, exploring: * sexual health and sexual satisfaction * pain severity and impact on daily activities * neuropathic pain * migraine * chemotherapy-induced peripheral neuropathy * quality of life, functioning, and symptoms * anxiety and depression * sociodemographic characteristics of patients * oncological characteristics

Eligibility criteria:
inclusion criteria: - declaring themselves to be suffering from or having suffered from cancer recruited as such via appropriate communication systems (patient associations and social networks, etc.) exclusion criteria: * no command of the french language * residence outside france (verified with the department of residence in the questionnaire) * patient companion * protected adult

Keywords: pain neuropathic pain sexual health cancer patients cancer survivors